Life sciences firms secured $1.8 billion in venture capital investments during the third quarter with 170 deals, an 18% drop from the second quarter, according to a PricewaterhouseCoopers report. Tracy Lefteroff of PwC US pointed to regulatory challenges, difficulty with IPOs and equity market volatility as reasons.
Biotech firms raised $1.8 billion in Q3 venture funding
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan
|Vice President of Finance||
Urban Health Plan, Inc.
|Director of Payor/Provider Contracting||
U.S. Medical Management